Table 1 Demographics and clinical characteristics of SteatoSITE cohort
| Â | NASH-CRN fibrosis stage | ||||
|---|---|---|---|---|---|
Variable | 0 | 1 | 2 | 3 | 4 |
Age, mean (s.d.) | |||||
 Years | 49.8 (13.9) | 53 (14.5) | 56.8 (13.6) | 59.1 (11.5) | 59.9 (9.8) |
Gender, number (%) | |||||
 Men | 137 (55.5) | 124 (59.6) | 92 (60.5) | 85 (50.3) | 83 (50.6) |
 Women | 110 (44.5) | 84 (40.4) | 60 (39.5) | 84 (49.7) | 81 (49.4) |
Ethnicity, number (%) | |||||
 White | 153 (16.3) | 137 (14.6) | 90 (9.6) | 106 (11.3) | 106 (11.3) |
 Asian | 8 (0.9) | 6 (0.6) | 3 (0.3) | 3 (0.3) | 2 (0.2) |
 African | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
 Unknown | 85 (9) | 65 (6.9) | 59 (6.3) | 60 (6.4) | 56 (6) |
BMI | |||||
 Median (IQR) | 30 (7.3) | 32.2 (10.3) | 31 (5.2) | 33.1 (7) | 31.7 (7.4) |
 Unknown BMI, number | 175 | 146 | 116 | 120 | 105 |
Diabetes, number (%) | |||||
 Yes | 33 (13.4) | 48 (23.1) | 42 (27.6) | 79 (46.7) | 105 (64) |
 No | 214 (86.6) | 160 (76.9) | 110 (72.4) | 90 (53.3) | 59 (36) |
SIMD quintile, number (%) | |||||
 1 | 21 (2.2) | 27 (2.9) | 23 (2.4) | 29 (3.1) | 25 (2.7) |
 2 | 19 (2) | 30 (3.2) | 14 (1.5) | 16 (1.7) | 26 (2.8) |
 3 | 28 (3) | 19 (2) | 17 (1.8) | 21 (2.2) | 24 (2.6) |
 4 | 23 (2.4) | 18 (1.9) | 10 (1.1) | 14 (1.5) | 23 (2.4) |
 5 | 43 (4.6) | 37 (3.9) | 32 (3.4) | 36 (3.8) | 26 (2.8) |
 Unknown SIMD | 113 (12) | 77 (8.2) | 56 (6) | 53 (5.6) | 40 (4.3) |
Liver enzymes, median (IQR) | |||||
 ALT (U per l) | 66 (78) | 90 (106.5) | 85 (109.5) | 77.5 (98.75) | 53 (110.25) |
 AST (U per l) | 38 (29) | 49 (42) | 48 (36.25) | 53 (46) | 44.5 (37.5) |
 ALP (U per l) | 88 (50.5) | 82.5 (43.75) | 81 (47) | 93.5 (53.5) | 107 (69) |
 Bilirubin (µmol per l) | 11 (9) | 11 (8.25) | 12 (10) | 14 (12) | 19 (37.5) |
Other laboratory results, median (IQR) | |||||
 Prothrombin time (s) | 12 (2) | 12 (2) | 12 (2) | 13 (1.25) | 14 (7) |
 INR | 1 (0.1) | 1 (0.1) | 1 (0.1) | 1.1 (0.2) | 1.2 (0.4) |
 Albumin (g per l) | 40 (10) | 39 (8) | 38 (12) | 37 (9) | 33.5 (16) |
 Platelets (×109 per l) | 237 (100) | 230 (94) | 213 (96.5) | 198 (104.75) | 130.5 (103) |
 Creatinine (µmol per l) | 73 (17) | 72 (21) | 75 (18.25) | 70 (22) | 71 (26) |
Non-invasive tests, median (IQR) | |||||
 FIB-4 | 1 (1) | 1.1 (1.2) | 1.4 (1.2) | 1.8 (1.8) | 2.4 (1.9) |
 Transient elastography (kPa) | 8.2 (5.7) | 10.9 (5.5) | 12.3 (6.9) | 14.4 (9.4) | 27.3 (34.3) |
Prescription, number (%) | |||||
 Statin | 19 (7.7) | 32 (15.4) | 18 (11.8) | 27 (16) | 32 (19.5) |
 Non-selective beta blocker | 1 (0.4) | 1 (0.5) | 5 (3.3) | 4 (2.4) | 7 (4.3) |
Specimen type, number (%) | |||||
 Biopsy | 198 (80.2) | 150 (72.1) | 100 (65.8) | 115 (68) | 96 (58.5) |
 Explant | 0 (0) | 0 (0) | 0 (0) | 2 (1.2) | 54 (32.9) |
 Resection | 49 (19.8) | 58 (27.9) | 52 (34.2) | 52 (30.8) | 14 (8.5) |
 Total case number | 247 | 208 | 152 | 169 | 164 |
